

# Yonyou (600588 CH)

## Striving for large-scale loss reduction in 2025

Yonyou hosted (2 April) an earnings conference call following its 2024 annual results. In 2024, Yonyou's total revenue reached RMB9.2bn, down 7% YoY, owing to postponed customer demand amid macro headwinds, and Yonyou's strategy to promote the subscription business model with greater intensity. Net loss attributable to ordinary shareholders expanded to RMB2.1bn in 2024 (2023: RMB967mn), mainly due to: 1) the decline in revenue generation; 2) compensation provided to the employees that have left their jobs; and 3) provisions for goodwill impairment. Management guided to strive for large-scale loss reduction in 2025 through improving labour productivity and improving the quality and efficiency of product delivery. Although we remain positive that Yonyou will benefit from increasing digitalization demand nationwide over the long term, and think the international expansion plan should help revive revenue growth in the coming years, we remain cautious in the near term. The 40% rise in its stock price YTD has largely priced in positive market sentiment regarding incremental benefits brought by the "DeepSeek moment", in our view, and concrete evidence on incremental monetization from AI is the next key to watch to drive a further rerating. We lift our TP to RMB14.49 (was RMB9.08) based on 5.3x 2025E EV/sales, in line with its two-year average. Maintain HOLD.

- **Solid progress made in large enterprise customer acquisition.** By the end of 2024, Yonyou recorded 7 new contract wins from central state-owned enterprises, bringing the total number of contract wins to 44. Revenue generation from the core BIP3 product reached RMB3.14bn in 2024, and its revenue contribution to total revenue was up by 2.4ppts YoY. The overall subscription revenue growth of 26% YoY was also higher than that of total revenue, demonstrating an improvement in revenue structure. Subscription related contract liabilities reached RMB2.31bn in 2024, up 25.9% YoY.
- **High R&D capitalization rate remains a concern.** In 2024, Yonyou's R&D expenditure came in at RMB2.1bn, flat YoY, which in our view demonstrated Yonyou's effort in optimizing cost while maintaining investment to drive product feature enhancement. However, R&D capitalization rate rose to a record high of 52% (vs. 48/50% in 2022/2023, compared to Kingdee's 32% in 2024). Although Yonyou suspended the disclosure of ARR contribution in 2024, it needs to improve ARR contribution and further optimize R&D capitalization, to drive a better long-term profitability outlook, in our view. The number of employees for Yonyou was 21,283, down 3,666 YoY (or 15% YoY), and we expect the improvement in labor productivity to help drive better operating efficiency ahead.
- **Maintain HOLD with a new TP of RMB14.49.** We lower 2025E and 2026E revenue forecast both by 18% to factor in slower-than-expected revenue growth in both large-sized enterprises and mid-sized enterprises. However, our TP is lifted to RMB14.49 based on 5.3x 2025E EV/sales (previously RMB9.08 on 3.1x 2024E EV/sales), in line with its two-year average, to factor in the industrywide rerating trend brought by more positive sentiment on AI-related monetization.

### Earnings Summary

(YE 31 Dec)	FY23A	FY24A	FY25E	FY26E	FY27E
Revenue (RMB mn)	9,796	9,153	9,982	11,081	12,233
YoY growth (%)	5.8	(6.6)	9.1	11.0	10.4
Net profit (RMB mn)	(967.2)	(2,061.3)	(426.0)	(25.2)	768.2
EPS (Reported) (RMB cents)	(28.29)	(60.32)	(12.47)	(0.74)	22.48
Consensus EPS (RMB cents)	0.00	0.00	(3.06)	13.72	27.20

Source: Company data, Bloomberg, CMBIGM estimates

## HOLD (Maintain)

**Target Price** RMB14.49  
 (Previous TP RMB9.08)  
**Up/Downside** (3.4%)  
**Current Price** RMB14.99

### China Software & IT Services

**Saiyi HE, CFA**  
 (852) 3916 1739  
 hesaiyi@cmbi.com.hk

**Ye TAO, CFA**  
 franktao@cmbi.com.hk

**Wentao LU, CFA**  
 luwentao@cmbi.com.hk

**Joanna Ma**  
 (852) 3761 8838  
 joannama@cmbi.com.hk

### Stock Data

Mkt Cap (RMB mn)	51,220.8
Avg 3 mths t/o (RMB mn)	1,826.5
52w High/Low (RMB)	20.00/8.13
Total Issued Shares (mn)	3417.0

Source: FactSet

### Shareholding Structure

Mr. Wang - Chairman	38.9%
HKSCC	7.9%


Source: Company data

### Share Performance

	Absolute	Relative
1-mth	-1.7%	-1.6%
3-mth	47.4%	44.8%
6-mth	30.3%	34.7%

Source: FactSet

### 12-mth Price Performance



Source: FactSet

**Figure 1: Yonyou: changes in CMBI forecast**


RMB mn	2025E			2026E			2027E		
	New	Old	%Diff	New	Old	%Diff	New	Old	%Diff
Sales	9,982	12,161	-18%	11,081	13,505	-18%	12,233	-	n/a
Gross profit	5,490	6,921	-21%	6,194	8,042	-23%	7,158	-	n/a
Operating profit	-533	193	-377%	-102	722	-114%	722	-	n/a
PBT	-412	215	-292%	22	770	-97%	904	-	n/a
Net profit	-426	183	-333%	-25	655	-104%	768	-	n/a
EPS	-0.12	0.05	-333%	-0.01	0.19	-104%	0.22	-	n/a
<b>Margins</b>									
GM	55.0%	56.9%	-192 bps	55.9%	59.5%	-365 bps	58.5%	-	n/a
OPM	-5.3%	1.6%	-692 bps	-0.9%	5.3%	-627 bps	5.9%	-	n/a
PBT margin	-4.1%	1.8%	-589 bps	0.2%	5.7%	-550 bps	7.4%	-	n/a
Net margin	-4.3%	1.5%	-577 bps	-0.2%	4.8%	-507 bps	6.3%	-	n/a

Source: CMBIGM estimates

**Figure 2: Yonyou: CMBI forecast vs Bloomberg consensus**

RMB mn	2025E			2026E			2027E		
	CMBI	Street	Diff	CMBI	Street	Diff	CMBI	Street	Diff
Sales	9,982	10,839	-8%	11,081	11,832	-6%	12,233	11,940	2%
Gross profit	5,490	5,761	-5%	6,194	6,536	-5%	7,158	6,977	3%
Operating profit	-533	-94	n/a	-102	448	-123%	722	984	-27%
PBT	-412	-97	n/a	22	530	-96%	904	952	-5%
Net profit	-426	-35	n/a	-25	473	-105%	768	782	-2%
EPS	-0.12	-0.03	n/a	-0.01	0.13	-106%	0.22	0.27	-17%
<b>Margins</b>									
GM	55.0%	53.2%	184 bps	55.9%	55.2%	66 bps	58.5%	58.4%	8 bps
OPM	-5.3%	-0.9%	-447 bps	-0.9%	3.8%	-471 bps	5.9%	8.2%	-234 bps
PBT margin	-4.1%	-0.9%	-323 bps	0.2%	4.5%	-428 bps	7.4%	8.0%	-59 bps
Net margin	-4.3%	-0.3%	-395 bps	-0.2%	4.0%	-422 bps	6.3%	6.6%	-27 bps

Source: Bloomberg, CMBIGM estimates

**Figure 3: Yonyou: EV/S valuation band over the past two years**

Source: Bloomberg, CMBIGM estimates

## Financial Summary

INCOME STATEMENT	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Revenue	9,262	9,796	9,153	9,982	11,081	12,233
Cost of goods sold	(4,041)	(4,826)	(4,802)	(4,493)	(4,887)	(5,075)
Gross profit	5,221	4,970	4,351	5,490	6,194	7,158
Operating expenses	(5,213)	(6,066)	(6,068)	(6,022)	(6,297)	(6,436)
Selling expense	(2,235)	(2,743)	(2,622)	(2,619)	(2,739)	(2,810)
Admin expense	(1,117)	(1,108)	(1,221)	(1,188)	(1,260)	(1,286)
R&D expense	(1,754)	(2,106)	(2,122)	(2,108)	(2,177)	(2,210)
Others	(106)	(108)	(104)	(108)	(120)	(130)
Operating profit	8	(1,096)	(1,717)	(533)	(102)	722
Interest expense	12	(68)	(115)	(70)	(88)	(40)
Other income/expense	227	254	(244)	191	213	222
Pre-tax profit	247	(910)	(2,076)	(412)	22	904
Income tax	(22)	(23)	6	(35)	(47)	(90)
After tax profit	225	(933)	(2,070)	(447)	(24)	813
Minority interest	(6)	(34)	9	21	(1)	(45)
Net profit	219	(967)	(2,061)	(426)	(25)	768

BALANCE SHEET	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Current assets	12,387	12,922	11,031	9,761	10,731	12,606
Cash & equivalents	8,304	8,045	6,424	5,101	5,464	6,699
Restricted cash	2,634	3,059	482	2,894	3,292	3,708
Account receivables	531	552	411	570	635	696
Other current assets	918	1,266	3,714	1,196	1,339	1,503
Non-current assets	11,168	12,599	13,126	13,068	12,483	11,604
PP&E	2,531	2,619	2,878	2,734	2,689	2,651
Intangibles	2,838	3,872	4,293	5,234	5,709	6,051
Other non-current assets	5,799	6,108	5,955	5,099	4,085	2,902
Total assets	23,555	25,521	24,157	22,829	23,214	24,210
Current liabilities	9,574	11,122	12,365	11,266	11,704	12,045
Short-term borrowings	3,611	4,240	5,592	5,294	5,057	4,686
Account payables	832	1,007	1,103	868	951	998
Other current liabilities	2,569	2,936	3,210	2,837	3,221	3,634
Accrued expenses	2,563	2,940	2,460	2,267	2,475	2,727
Non-current liabilities	1,463	2,596	1,992	2,189	2,162	2,049
Long-term borrowings	826	1,910	1,433	1,629	1,602	1,489
Other non-current liabilities	637	685	560	560	560	560
Total liabilities	11,037	13,718	14,357	13,455	13,866	14,094
Share capital	3,434	3,419	3,417	3,417	3,417	3,417
Capital surplus	5,852	5,290	5,433	5,433	5,433	5,433
Retained earnings	3,369	2,198	137	(289)	(314)	454
Other reserves	(1,193)	(754)	(740)	(740)	(740)	(740)
Total shareholders equity	11,461	10,152	8,247	7,821	7,795	8,564
Minority interest	1,057	1,651	1,553	1,553	1,553	1,553
Total equity and liabilities	23,555	25,521	24,157	22,829	23,214	24,210

CASH FLOW	2022A	2023A	2024A	2025E	2026E	2027E
<b>YE 31 Dec (RMB mn)</b>						
<b>Operating</b>						
Profit before taxation	247	(910)	(2,076)	(412)	22	904
Depreciation & amortization	579	855	1,134	948	1,105	1,271
Tax paid	(22)	(23)	6	(35)	(47)	(90)
Change in working capital	(819)	338	37	(854)	69	71
Others	301	(350)	626	0	0	0
<b>Net cash from operations</b>	<b>286</b>	<b>(91)</b>	<b>(274)</b>	<b>(353)</b>	<b>1,150</b>	<b>2,156</b>
<b>Investing</b>						
Capital expenditure	(1,557)	(1,797)	(1,759)	(1,455)	(1,535)	(1,576)
Others	(2,296)	1,254	651	566	1,015	1,183
<b>Net cash from investing</b>	<b>(3,853)</b>	<b>(542)</b>	<b>(1,108)</b>	<b>(890)</b>	<b>(520)</b>	<b>(393)</b>
<b>Financing</b>						
Dividend paid	(344)	(206)	0	0	0	0
Net borrowings	1,077	1,829	819	(101)	(265)	(483)
Others	6,508	(1,252)	(1,057)	21	(1)	(45)
<b>Net cash from financing</b>	<b>7,241</b>	<b>372</b>	<b>(238)</b>	<b>(80)</b>	<b>(266)</b>	<b>(529)</b>
<b>Net change in cash</b>						
Cash at the beginning of the year	4,616	8,304	8,045	6,424	5,101	5,464
Exchange difference	14	3	(2)	0	0	0
<b>Cash at the end of the year</b>	<b>8,304</b>	<b>8,045</b>	<b>6,424</b>	<b>5,101</b>	<b>5,464</b>	<b>6,699</b>
GROWTH	2022A	2023A	2024A	2025E	2026E	2027E
<b>YE 31 Dec</b>						
Revenue	3.7%	5.8%	(6.6%)	9.1%	11.0%	10.4%
Gross profit	(4.6%)	(4.8%)	(12.5%)	26.2%	12.8%	15.6%
Operating profit	(98.6%)	na	na	na	na	na
Net profit	(69.0%)	na	na	na	na	na
PROFITABILITY	2022A	2023A	2024A	2025E	2026E	2027E
<b>YE 31 Dec</b>						
Gross profit margin	56.4%	50.7%	47.5%	55.0%	55.9%	58.5%
Operating margin	0.1%	(11.2%)	(18.8%)	(5.3%)	(0.9%)	5.9%
Return on equity (ROE)	2.4%	(8.9%)	(22.4%)	(5.3%)	(0.3%)	9.4%
GEARING/LIQUIDITY/ACTIVITIES	2022A	2023A	2024A	2025E	2026E	2027E
<b>YE 31 Dec</b>						
Net debt to equity (x)	(0.3)	(0.2)	0.1	0.2	0.2	(0.1)
Current ratio (x)	1.3	1.2	0.9	0.9	0.9	1.0
Receivable turnover days	82.9	106.1	70.6	61.7	101.9	104.4
Inventory turnover days	18.5	20.2	19.2	17.9	19.8	19.9
Payable turnover days	75.1	37.5	44.0	31.7	31.3	29.8
VALUATION	2022A	2023A	2024A	2025E	2026E	2027E
<b>YE 31 Dec</b>						
P/E	234.8	ns	ns	ns	ns	66.7
P/B	4.1	4.3	5.2	5.5	5.5	5.1
Div yield (%)	0.7	0.4	0.0	0.0	0.0	0.0
EV	48,652.5	51,218.5	53,615.7	54,837.9	54,209.3	52,491.2
EV/Sales	5.3	5.2	5.9	5.5	4.9	4.3

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

# Disclosures & Disclaimers

## Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## CMBIGM Ratings

**BUY** : Stock with potential return of over 15% over next 12 months  
**HOLD** : Stock with potential return of +15% to -10% over next 12 months  
**SELL** : Stock with potential loss of over 10% over next 12 months  
**NOT RATED** : Stock is not rated by CMBIGM

**OUTPERFORM** : Industry expected to outperform the relevant broad market benchmark over next 12 months  
**MARKET-PERFORM** : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months  
**UNDERPERFORM** : Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

**Address:** 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

**CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)**

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

### For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

### For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.